{"id":"irbesartan-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia (irbesartan component)"},{"rate":null,"effect":"Hypokalemia (hydrochlorothiazide component)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL435","moleculeType":"Small molecule","molecularWeight":"297.75"},"_dailymed":{"setId":"53ce6e4f-db3a-4789-8bef-1e459fa78b79","title":"IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLET [BRYANT RANCH PREPACK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the adrenal gland, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion. Together, these complementary mechanisms provide additive blood pressure reduction.","oneSentence":"Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:12.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Hypertension in patients with type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":"Arterial Hypertension","enrollment":94},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT01712126","phase":"NA","title":"Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-09","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01712139","phase":"NA","title":"Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-09","conditions":"Hypertension","enrollment":37},{"nctId":"NCT00219115","phase":"PHASE3","title":"A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Hypertension","enrollment":493},{"nctId":"NCT00987662","phase":"PHASE4","title":"Irbesartan Versus Amlodipine: The OBI Study","status":"WITHDRAWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":"Obesity, Hypertension","enrollment":""},{"nctId":"NCT01858610","phase":"NA","title":"Drug Interaction Between Irbesartan and Hydrochlorothiazide","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2013-03","conditions":"Healthy","enrollment":18},{"nctId":"NCT00713011","phase":"PHASE3","title":"Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2008-11","conditions":"Diabetic Nephropathies, Hypertension","enrollment":""},{"nctId":"NCT00362037","phase":"PHASE4","title":"I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Hypertension","enrollment":281},{"nctId":"NCT00095394","phase":"PHASE3","title":"Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-09","conditions":"Hypertension","enrollment":645},{"nctId":"NCT00095550","phase":"PHASE3","title":"Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-10","conditions":"Hypertension","enrollment":496},{"nctId":"NCT00110422","phase":"PHASE4","title":"Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"Metabolic Syndrome, Hypertension","enrollment":400},{"nctId":"NCT00362258","phase":"PHASE4","title":"I PREVENT - Irbesartan In Hypertensive Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hypertension","enrollment":797},{"nctId":"NCT00335673","phase":"PHASE4","title":"I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hypertension","enrollment":1630},{"nctId":"NCT00224549","phase":"PHASE4","title":"PHARES Study: Management of Resistant Hypertension","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-04","conditions":"Hypertension","enrollment":180},{"nctId":"NCT00500604","phase":"PHASE4","title":"Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-07","conditions":"Hypertension","enrollment":1617},{"nctId":"NCT00708344","phase":"PHASE4","title":"ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Hypertension","enrollment":832},{"nctId":"NCT01020240","phase":"NA","title":"Physiotherapy in Postpartum After a Cesarean","status":"COMPLETED","sponsor":"Sao Marcos University","startDate":"2009-03","conditions":"Postpartum Period","enrollment":45},{"nctId":"NCT00443612","phase":"PHASE4","title":"Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Hypertension","enrollment":60},{"nctId":"NCT00670566","phase":"PHASE4","title":"Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-04","conditions":"Hypertension","enrollment":503},{"nctId":"NCT00847834","phase":"PHASE4","title":"Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-12","conditions":"Hypertension","enrollment":968},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00264212","phase":"PHASE4","title":"AMISH : Aprovel for Management of Isolated Systolic Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Hypertension","enrollment":436},{"nctId":"NCT00263003","phase":"PHASE3","title":"Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-06","conditions":"Hypertension","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":44,"reaction":"FATIGUE"},{"count":39,"reaction":"DRUG INTERACTION"},{"count":39,"reaction":"DYSPNOEA"},{"count":38,"reaction":"DIARRHOEA"},{"count":37,"reaction":"HYPOTENSION"},{"count":36,"reaction":"HYPONATRAEMIA"},{"count":33,"reaction":"NAUSEA"},{"count":33,"reaction":"VOMITING"},{"count":29,"reaction":"FALL"},{"count":28,"reaction":"ACUTE KIDNEY INJURY"}],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Irbesartan - Hydrochlorothiazide","genericName":"Irbesartan - Hydrochlorothiazide","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume. Used for Hypertension, Hypertension in patients with type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}